Aug 9, 2018
Soligenix BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate, OrbeShield®
Loading...
seen from United States
seen from China
seen from United States
seen from Iraq
seen from Germany
seen from United States
seen from Yemen
seen from Switzerland
seen from United States
seen from Russia
seen from China
seen from China
seen from United States
seen from France
seen from United States
seen from United States
seen from China
seen from Brazil
seen from Brazil
seen from United States
Soligenix BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate, OrbeShield®
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTC:SNGX) to $4.00
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTC:SNGX) to $4.00
Analyst Ratings For Soligenix (OTC:SNGX) Today, Maxim Group raised its price target on Soligenix (OTC:SNGX) to $4.00 per share. There are 1 buy rating on the stock. The current consensus rating on Soligenix (OTC:SNGX) is Buy (Score: 3.00) with a consensus target price of $4.00 per share, a potential . Some recent analyst ratings include Dividend information for Soligenix (OTC:SNGX) . About…
View On WordPress
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTCBB:SNGX) to $4.00
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTCBB:SNGX) to $4.00
Analyst Ratings For Soligenix (OTCBB:SNGX) Today, Maxim Group raised its price target on Soligenix (OTCBB:SNGX) to $4.00 per share. There are 2 buy ratings on the stock. The current consensus rating on Soligenix (OTCBB:SNGX) is Buy (Score: 3.00) with a consensus target price of $5.00 per share, a potential . Some recent analyst ratings include 9/7/2016-Aegis initiated coverage with a Buy rating.…
View On WordPress